Corrigendum to ‘IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications’: [Annals of Oncology 34 (2023) p693-702, (S0923753423006944), (10.1016/j.annonc.2023.05.009)]

M. Burotto; Z. Zvirbule; A. Mochalova; Y. Runglodvatana; L. Herraez-Baranda; S. N. Liu; P. Chan; E. Shearer-Kang; X. Liu; N. Tosti; J. A. Zanghi; B. Leutgeb; E. Felip

doi:10.1016/j.annonc.2023.12.005

Corrigendum to ‘IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications’: [Annals of Oncology 34 (2023) p693-702, (S0923753423006944), (10.1016/j.annonc.2023.05.009)]

M. Burotto^*, Z. Zvirbule, A. Mochalova, Y. Runglodvatana, L. Herraez-Baranda, S. N. Liu, P. Chan, E. Shearer-Kang, X. Liu, N. Tosti, J. A. Zanghi, B. Leutgeb, E. Felip

^*Autor correspondiente de este trabajo

Producción científica: Contribución a una revista › Comentario/Debate

Resumen

The authors regret that there was an error to the Results section, page 697, of the published manuscript. The corrected sentence is shown below: Serious AEs occurred in 15.4% (n ¼ 38) of patients receiving atezolizumab SC and 17.7% (n ¼ 22) of patients receiving atezolizumab IV (Table 2). The authors would like to apologise for any inconvenience caused.

Idioma original	Inglés
Publicación	Annals of Oncology
DOI	https://doi.org/10.1016/j.annonc.2023.12.005
Estado	Aceptada/en prensa - 2024
Publicado de forma externa	Sí

Nota bibliográfica

Publisher Copyright:
© 2023 European Society for Medical Oncology

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.1016/j.annonc.2023.12.005

Otros archivos y enlaces

Enlace a la publicación en Scopus

Huella

Profundice en los temas de investigación de 'Corrigendum to ‘IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications’: [Annals of Oncology 34 (2023) p693-702, (S0923753423006944), (10.1016/j.annonc.2023.05.009)]'. En conjunto forman una huella única.

Citar esto

Burotto, M., Zvirbule, Z., Mochalova, A., Runglodvatana, Y., Herraez-Baranda, L., Liu, S. N., Chan, P., Shearer-Kang, E., Liu, X., Tosti, N., Zanghi, J. A., Leutgeb, B., & Felip, E. (Aceptado/En prensa). Corrigendum to ‘IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications’: [Annals of Oncology 34 (2023) p693-702, (S0923753423006944), (10.1016/j.annonc.2023.05.009)]. Annals of Oncology. https://doi.org/10.1016/j.annonc.2023.12.005

Burotto, M. ; Zvirbule, Z. ; Mochalova, A. et al. / Corrigendum to ‘IMscin001 Part 2 : a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications’: [Annals of Oncology 34 (2023) p693-702, (S0923753423006944), (10.1016/j.annonc.2023.05.009)]. En: Annals of Oncology. 2024.

@article{88b4ebe9bd2046cfb4bb91d338b6ab03,

title = "Corrigendum to {\textquoteleft}IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications{\textquoteright}: [Annals of Oncology 34 (2023) p693-702, (S0923753423006944), (10.1016/j.annonc.2023.05.009)]",

abstract = "The authors regret that there was an error to the Results section, page 697, of the published manuscript. The corrected sentence is shown below: Serious AEs occurred in 15.4% (n ¼ 38) of patients receiving atezolizumab SC and 17.7% (n ¼ 22) of patients receiving atezolizumab IV (Table 2). The authors would like to apologise for any inconvenience caused.",

author = "M. Burotto and Z. Zvirbule and A. Mochalova and Y. Runglodvatana and L. Herraez-Baranda and Liu, {S. N.} and P. Chan and E. Shearer-Kang and X. Liu and N. Tosti and Zanghi, {J. A.} and B. Leutgeb and E. Felip",

note = "Publisher Copyright: {\textcopyright} 2023 European Society for Medical Oncology",

year = "2024",

doi = "10.1016/j.annonc.2023.12.005",

language = "English",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

}

Burotto, M, Zvirbule, Z, Mochalova, A, Runglodvatana, Y, Herraez-Baranda, L, Liu, SN, Chan, P, Shearer-Kang, E, Liu, X, Tosti, N, Zanghi, JA, Leutgeb, B & Felip, E 2024, 'Corrigendum to ‘IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications’: [Annals of Oncology 34 (2023) p693-702, (S0923753423006944), (10.1016/j.annonc.2023.05.009)]', Annals of Oncology. https://doi.org/10.1016/j.annonc.2023.12.005

Corrigendum to ‘IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications’: [Annals of Oncology 34 (2023) p693-702, (S0923753423006944), (10.1016/j.annonc.2023.05.009)]. / Burotto, M.; Zvirbule, Z.; Mochalova, A. et al.
En: Annals of Oncology, 2024.

Producción científica: Contribución a una revista › Comentario/Debate

TY - JOUR

T1 - Corrigendum to ‘IMscin001 Part 2

T2 - a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications’: [Annals of Oncology 34 (2023) p693-702, (S0923753423006944), (10.1016/j.annonc.2023.05.009)]

AU - Burotto, M.

AU - Zvirbule, Z.

AU - Mochalova, A.

AU - Runglodvatana, Y.

AU - Herraez-Baranda, L.

AU - Liu, S. N.

AU - Chan, P.

AU - Shearer-Kang, E.

AU - Liu, X.

AU - Tosti, N.

AU - Zanghi, J. A.

AU - Leutgeb, B.

AU - Felip, E.

PY - 2024

Y1 - 2024

N2 - The authors regret that there was an error to the Results section, page 697, of the published manuscript. The corrected sentence is shown below: Serious AEs occurred in 15.4% (n ¼ 38) of patients receiving atezolizumab SC and 17.7% (n ¼ 22) of patients receiving atezolizumab IV (Table 2). The authors would like to apologise for any inconvenience caused.

AB - The authors regret that there was an error to the Results section, page 697, of the published manuscript. The corrected sentence is shown below: Serious AEs occurred in 15.4% (n ¼ 38) of patients receiving atezolizumab SC and 17.7% (n ¼ 22) of patients receiving atezolizumab IV (Table 2). The authors would like to apologise for any inconvenience caused.

UR - http://www.scopus.com/inward/record.url?scp=85182354513&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2023.12.005

DO - 10.1016/j.annonc.2023.12.005

M3 - Comment/debate

C2 - 38195363

AN - SCOPUS:85182354513

SN - 0923-7534

JO - Annals of Oncology

JF - Annals of Oncology

ER -

Burotto M, Zvirbule Z, Mochalova A, Runglodvatana Y, Herraez-Baranda L, Liu SN et al. Corrigendum to ‘IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications’: [Annals of Oncology 34 (2023) p693-702, (S0923753423006944), (10.1016/j.annonc.2023.05.009)]. Annals of Oncology. 2024. doi: 10.1016/j.annonc.2023.12.005